140 related articles for article (PubMed ID: 29674631)
1. Orally active, species-independent novel A
Dorotea D; Cho A; Lee G; Kwon G; Lee J; Sahu PK; Jeong LS; Cha DR; Ha H
Exp Mol Med; 2018 Apr; 50(4):1-14. PubMed ID: 29674631
[TBL] [Abstract][Full Text] [Related]
2. Dual Actions of A
Pak ES; Jeong LS; Hou X; Tripathi SK; Lee J; Ha H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073488
[TBL] [Abstract][Full Text] [Related]
3. The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis.
Lee J; Hwang I; Lee JH; Lee HW; Jeong LS; Ha H
Am J Pathol; 2013 Nov; 183(5):1488-1497. PubMed ID: 24001475
[TBL] [Abstract][Full Text] [Related]
4. LJ-529, a partial peroxisome proliferator-activated receptor gamma (PPARγ) agonist and adenosine A
Boo HJ; Park SJ; Noh M; Min HY; Jeong LS; Lee HY
Arch Pharm Res; 2020 May; 43(5):540-552. PubMed ID: 32430718
[TBL] [Abstract][Full Text] [Related]
5. PGC-1α ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism.
Zhang L; Liu J; Zhou F; Wang W; Chen N
Mol Med Rep; 2018 Mar; 17(3):4490-4498. PubMed ID: 29344670
[TBL] [Abstract][Full Text] [Related]
6. A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats.
Dorotea D; Kwon G; Lee JH; Saunders E; Bae YS; Moon SH; Lee SJ; Cha DR; Ha H
Pharmacology; 2018; 102(3-4):180-189. PubMed ID: 30099457
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system inhibition reverses the altered triacylglycerol metabolic network in diabetic kidney disease.
Sas KM; Lin J; Wang CH; Zhang H; Saha J; Rajendiran TM; Soni T; Nair V; Eichinger F; Kretzler M; Brosius FC; Michailidis G; Pennathur S
Metabolomics; 2021 Jul; 17(7):65. PubMed ID: 34219205
[TBL] [Abstract][Full Text] [Related]
8. ATF5 regulates tubulointerstitial injury in diabetic kidney disease via mitochondrial unfolded protein response.
Liu Y; Zhang L; Zhang S; Liu J; Li X; Yang K; Yang D; Liu Y; Sun L; Liu F; Xiao L
Mol Med; 2023 Apr; 29(1):57. PubMed ID: 37095454
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective Effects of a Highly Selective A3 Adenosine Receptor Antagonist in a Mouse Model of Adriamycin-induced Nephropathy.
Min HS; Cha JJ; Kim K; Kim JE; Ghee JY; Kim H; Lee JE; Han JY; Jeong LS; Cha DR; Kang YS
J Korean Med Sci; 2016 Sep; 31(9):1403-12. PubMed ID: 27510383
[TBL] [Abstract][Full Text] [Related]
10. Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db/db mice.
Liu W; Chen X; Wang Y; Chen Y; Chen S; Gong W; Chen T; Sun L; Zheng C; Yin B; Li S; Luo C; Huang Q; Xiao J; Xu Z; Peng F; Long H
Pharmacol Res; 2019 Dec; 150():104506. PubMed ID: 31669149
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease.
Maekawa M; Maekawa T; Sasase T; Takagi K; Takeuchi S; Kitamoto M; Nakagawa T; Toyoda K; Konishi N; Ohta T; Yamada T
Physiol Res; 2022 Apr; 71(2):209-217. PubMed ID: 35344670
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors.
Carlin JL; Tosh DK; Xiao C; Piñol RA; Chen Z; Salvemini D; Gavrilova O; Jacobson KA; Reitman ML
J Pharmacol Exp Ther; 2016 Feb; 356(2):474-82. PubMed ID: 26606937
[TBL] [Abstract][Full Text] [Related]
13. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
14. Adenosine receptors as emerging therapeutic targets for diabetic kidney disease.
Pak ES; Cha JJ; Cha DR; Kanasaki K; Ha H
Kidney Res Clin Pract; 2022 Sep; 41(Suppl 2):S74-S88. PubMed ID: 36239063
[TBL] [Abstract][Full Text] [Related]
15. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis.
Kwon G; Uddin MJ; Lee G; Jiang S; Cho A; Lee JH; Lee SR; Bae YS; Moon SH; Lee SJ; Cha DR; Ha H
Oncotarget; 2017 Sep; 8(43):74217-74232. PubMed ID: 29088780
[TBL] [Abstract][Full Text] [Related]
16. LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice.
Park JG; Jeong SJ; Yu J; Kim G; Jeong LS; Oh GT
BMB Rep; 2018 Oct; 51(10):520-525. PubMed ID: 29936931
[TBL] [Abstract][Full Text] [Related]
17. Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.
Auchampach JA; Jin X; Wan TC; Caughey GH; Linden J
Mol Pharmacol; 1997 Nov; 52(5):846-60. PubMed ID: 9351976
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term A3 adenosine receptor activation inhibits the Na+/H+ exchanger NHE3 activity and expression in opossum kidney cells.
Di Sole F; Cerull R; Babich V; Casavola V; Helmle-Roth C; Burckhardt G
J Cell Physiol; 2008 Jul; 216(1):221-33. PubMed ID: 18286509
[TBL] [Abstract][Full Text] [Related]
19. The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers.
Chung H; Jung JY; Cho SD; Hong KA; Kim HJ; Shin DH; Kim H; Kim HO; Shin DH; Lee HW; Jeong LS; Kong G
Mol Cancer Ther; 2006 Mar; 5(3):685-92. PubMed ID: 16546983
[TBL] [Abstract][Full Text] [Related]
20. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
